聚ADP核糖聚合酶-1与原发性肝癌的研究进展
Research Progress of PARP1 in Hepatocellular Carcinoma
摘要: 最新统计数据表明，原发性肝癌(hepatocellular carcinoma, HCC)是世界上第二大致病率肿瘤，它有很高的复发率及很低的5年生存率，且它的治疗选择有限。然而每年的新发例数却在逐年增加。找到原发性肝癌复发、转移及耐药的机制是我们亟待解决的问题。聚ADP核糖聚合酶-1 (poly(ADP)-ribose polymerase, PARP1)是一个分子量为116 kDa的细胞核蛋白，它在多种肿瘤当中异常表达，包括卵巢癌、乳腺癌、前列腺癌、胰腺以及原发性肝癌。近年来目前上市的PARP抑制剂(PARP inhibitor, PARPi)药物，在乳腺及卵巢癌中应用广泛，但在原发性肝癌中不尽如意。原发性肝癌具有异质性，其发生与发展是一个多途径、多基因参与及多步骤的过程，其发病率与病死率在中国逐年上升。研究发现，PARP1与HCC的发生、发展及治疗密切相关，本文从PARP1的分子结构及生物学功能、PARPi的作用机制、PARP1在HCC组织中的表达情况、PARPi与HCC治疗的关系等4个方面对PARPi在HCC中作用的研究进展作一系统综述，为临床治疗HCC寻找新的治疗策略。
Abstract: The latest statistics show that hepatocellular carcinoma (HCC) is the second most morbid tumor in the world, which has a high recurrence rate, a low 5-year survival rate, and its treatment options are limited. However, the number of new cases is increasing year by year. It is urgent to find out the mechanism of recurrence, metastasis and drug resistance of HCC. Poly ADP-ribose polymerase-1 (poly(ADP)-ribose polymerase, PARP1) is a nuclear protein with a molecular weight of 116 kDa which is abnormally expressed in a variety of tumors, including ovarian cancer, breast cancer, prostate cancer, Pancreatic cancer and HCC. In recent years, the PARP inhibitor (PARPi) drugs cur-rently are widely used in breast and ovarian cancer. However, they are not satisfactory in HCC. HCC is a multi-path, multi-gene and multi-step process for its occurrence and development. Studies have found that PARP1 is closely related to the occurrence, development and treatment of HCC. This study focuses on the molecular structure and biological function of PARP1, the mechanism of action of PARPi, the expression of PARP1 in HCC tissue, and the relationship between PARPi and HCC treatment. A systematic review of the research progress of the role of PARPi in HCC was made to find new therapeutic strategies for clinical treatment of HCC.
文章引用：阙克婷, 刘作金, 李钺. 聚ADP核糖聚合酶-1与原发性肝癌的研究进展[J]. 临床医学进展, 2022, 12(7): 6893-6899. https://doi.org/10.12677/ACM.2022.127994

参考文献

[1] Gibson, B. and Kraus, W.L. (2012) New Insights into the Molecular and Cellular Functions of Poly(ADP-Ribose) and PARPs. Nature Reviews Molecular Cell Biology, 13, 411-424. [Google Scholar] [CrossRef] [PubMed]
[2] Curtin, N.J. and Szabo C. (2020) Poly(ADP-Ribose) Polymerase Inhibition: Past, Present and Future. Nature Reviews Drug Discov-ery, 19, 711-736. [Google Scholar] [CrossRef] [PubMed]
[3] Lee Kraus, W. (2015) PARPs and ADP-Ribosylation: 50 Years … and Counting. Molecular Cell, 58, 902-910. [Google Scholar] [CrossRef] [PubMed]
[4] Langelier, M.F., Planck, J.L., Roy, S. and Pascal, J.M. (2012) Structural Basis for DNA Damage-Dependent Poly(ADP- ribosyl)ation by Human PARP-1. Science, 336, 728-732. [Google Scholar] [CrossRef] [PubMed]
[5] Lord, C.J. and Ashworth, A. (2017) PARP Inhibitors: Synthetic Le-thality in the Clinic. Science, 355, 1152-1158. [Google Scholar] [CrossRef] [PubMed]
[6] Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., et al. (2005) Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy. Na-ture, 434, 917-921. [Google Scholar] [CrossRef] [PubMed]
[7] Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., et al. (2005) Specific Killing of BRCA2-Deficient Tumours with Inhibitors of Poly(ADP-Ribose) Polymerase. Nature, 434, 913-917. [Google Scholar] [CrossRef] [PubMed]
[8] Faraoni, I. and Graziani, G. (2018) Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers, 10, Article No. 487. [Google Scholar] [CrossRef] [PubMed]
[9] 中华医学会妇科肿瘤学分会. 卵巢癌PARP抑制剂临床应用指南[J]. 中国医学前沿杂志(电子版), 2020, 12(5): 29-37.
[10] Chauhan, R. and Michalak, T.I. (2020) Kinetics of DNA Damage Repair Response Accompanying Initial Hepadnavirus-Host Genomic Integration in Woodchuck Hepatitis Virus Infection of Hepatocyte. Cancer Genet, 244, 1-10. [Google Scholar] [CrossRef] [PubMed]
[11] Funato, K., Otsuka, M., Sekiba, K., Miyakawa, Y., Seimiya, T., Shibata, C., et al. (2022) Hepatitis B Virus-Associated Hepatocellular Carcinoma with Smc5/6 Complex Deficiency Is Susceptible to PARP Inhibitors. Biochemical and Biophysical Research Communications, 607, 89-95. [Google Scholar] [CrossRef] [PubMed]
[12] Makokha, G.N., Abe-Chayama, H., Chowdhury, S., Hayes, C.N., Tsuge, M., Yoshima, T., et al. (2019) Regulation of the Hepatitis B Virus Replication and Gene Expression by the Mul-ti-Functional Protein TARDBP. Scientific Reports, 9, Article No. 8462. [Google Scholar] [CrossRef] [PubMed]
[13] Sun, Y., Wu, L., Zhong, Y., Zhou, K., Hou, Y., Wang, Z., et al. (2021) Single-Cell Landscape of the Ecosystem in Early-Relapse Hepatocellular Carcinoma. Cell, 184, 404-421.e16. [Google Scholar] [CrossRef] [PubMed]
[14] Cancer Genome Atlas Research Network (2017) Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 169, 1327-1341.e23. [Google Scholar] [CrossRef] [PubMed]
[15] Zhang, X., Wang, Y., Gari, A., Qu, C. and Chen, J. (2021) Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Asso-ciation of Its Expression Levels and Immunotherapy Signatures. Frontiers in Immunology, 12, Article ID: 721030. [Google Scholar] [CrossRef] [PubMed]
[16] Li, J., Dou, D., Li, P., Luo, W., Lv, W., Zhang, C., et al. (2017) PARP-1 Serves as a Novel Molecular Marker for Hepatocellular Carcinoma in a Southern Chinese Zhuang Population. Tumor Biology, 39, Article ID: 1010428317706914. [Google Scholar] [CrossRef] [PubMed]
[17] Ohri, N., Dawson, L.A., Krishnan, S., Seong, J., Cheng, J.C., Sarin, S.K., et al. (2016) Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. Journal of the National Cancer Institute, 108, djw133. [Google Scholar] [CrossRef] [PubMed]
[18] Chino, F., Stephens, S.J., Choi, S.S., Marin, D., Kim, C.Y., Morse, M.A., et al. (2018) The Role of External Beam Radiotherapy in the Treatment of Hepatocellular Cancer. Cancer, 124, 3476-3489. [Google Scholar] [CrossRef] [PubMed]
[19] Guillot, C., Favaudon, V., Herceg, Z., Sagne, C., Sauvaigo, S., Merle, P., et al. (2014) PARP Inhibition and the Radiosensitizing Effects of the PARP Inhibitor ABT-888 in in Vitro Hepatocellular Carcinoma Models. BMC Cancer, 14, Article No. 603. [Google Scholar] [CrossRef] [PubMed]
[20] Gerossier, L., Dubois, A., Paturel, A., Fares, N., Cohen, D., Merle, P., et al. (2021) PARP Inhibitors and Radiation Potentiate Liver Cell Death in Vitro. Do Hepatocellular Carcinomas Have an Achilles’ Heel? Clinics and Research in Hepatology and Gastroenterology, 45, Article ID: 101553. [Google Scholar] [CrossRef] [PubMed]
[21] Bishara, L.A., Machour, F.E., Awwad, S.W. and Ayoub, N. (2021) NELF Complex Fosters BRCA1 and RAD51 Recruitment to DNA Damage Sites and Modulates Sensitivity to PARP Inhibition. DNA Repair, 97, Article ID: 103025. [Google Scholar] [CrossRef] [PubMed]
[22] Yang, X.D., Kong, F.E., Qi, L., Lin, J.X., Yan, Q., Loong, J.H.C., et al. (2021) PARP Inhibitor Olaparib Overcomes Sorafenib Resistance through Reshaping the Pluripotent Tran-scriptome in Hepatocellular Carcinoma. Molecular Cancer, 20, Article No. 20. [Google Scholar] [CrossRef] [PubMed]
[23] Xu, H., Ma, Z., Mo, X., Chen, X., Xu, F., Wu, F., et al. (2022) Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma. Journal of Cancer, 13, 2226-2237. [Google Scholar] [CrossRef] [PubMed]
[24] Dong, Q., Du, Y., Li, H., Liu, C., Wei, Y., Chen, M.K., et al. (2019) EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Research, 79, 819-829. [Google Scholar] [CrossRef] 
[25] Sen, T., Rodriguez, B.L., Chen, L., Corte, C.M.D., Mori-kawa, N., Fujimoto, J., et al. (2019) Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery, 9, 646-661. [Google Scholar] [CrossRef] 
[26] Zhou, B., Guo, L., Zhang, B., Liu, S., Zhang, K., et al. (2019) Disulfiram Combined with Copper Induces Immunosuppression via PD-L1 Stabilization in Hepatocellular Carcinoma. American Journal of Cancer Research, 9, 2442-2455. [Google Scholar] [CrossRef] [PubMed]
[27] Zhou, B., Yan, J., Guo, L., Zhang, B., Liu, S., Yu, M., et al. (2020) He-patoma Cell-Intrinsic TLR9 Activation Induces Immune Escape through PD-L1 Upregulation in Hepatocellular Carcino-ma. Theranostics, 10, 6530-6543.
[28] Li, C.X., Shao, Y., Ng, K.T., Liu, X.B., Ling, C.C., Ma, Y.Y., et al. (2012) FTY720 Suppresses Liver Tumor Metastasis by Reducing the Population of Circulating Endothelial Progenitor Cells. PLOS ONE, 7, e32380. [Google Scholar] [CrossRef] [PubMed]
[29] Li, C.X., Wong, B.L., Ling, C.C., Ma, Y.Y., Shao, Y., Geng, W., et al. (2014) A Novel Oxygen Carrier “YQ23” Suppresses the Liver Tumor Metastasis by Decreasing Circulating Endothelial Progenitor Cells and Regulatory T cells. BMC Cancer, 14, Article No. 293. [Google Scholar] [CrossRef] [PubMed]
[30] Wang, S., Yang, F.J., Wang, X., Zhou, Y., Dai, B., Han, B., et al. (2017) PARP-1 Promotes Tumor Recurrence after Warm Ischemic Liver Graft Transplantation via Neutrophil Recruit-ment and Polarization. Oncotarget, 8, 88918-88933. [Google Scholar] [CrossRef] [PubMed]

为你推荐